Abstract
Backgroun/Methods: In attempt to develop new potent anti-tumor agents, a series of quinoxaline derivatives was designed and synthesized. The novel compounds were tested in vitro for their anti-proliferative activities against HePG-2, MCF-7 and HCT-116 cell lines. Additionally, DNA binding affinities as well as DNA-top II inhibitory activities of the synthesized compounds were investigated as potential mechanism for anticancer activity. Compounds 13, 15, 16 and 19 exhibited good cytotoxicity activities against the three cell lines (IC50 ranging from 7.6 to 32.4 µM) comparable to that of doxorubicin (IC50 = 9.8 µM).
Results: Interestingly, the results of DNA binding and DNA-top II inhibition assays were in agreement with those of the cytotoxicity tests, where the most potent anticancer compounds showed good DNA binding affinities (IC50 ranging from 25.1 to 32.4 µM) and DNA-top II inhibitory activities (IC50 ranging from 6.4 to 15.3 µM) comparable to those of doxorubicin (IC50 = 28.1 and 3.8 μM, respectively). Furthermore, molecular docking studies were carried out for the new compounds in order to investigate their binding pattern with the prospective target, DNA-top II complex (PDB-code: 3qx3).
Keywords: Anti-cancer, topoisomerase II, DNA intercalators, quinoxaline, docking.
Anti-Cancer Agents in Medicinal Chemistry
Title:Design and Discovery of Novel Quinoxaline Derivatives as Dual DNA Intercalators and Topoisomerase II Inhibitors
Volume: 18 Issue: 2
Author(s): Ibrahim H. Eissa, Abeer M. El-Naggar*, Nour E.A. Abd El-Sattar and Ahmed S. A. Youssef
Affiliation:
- Chemistry Department, Faculty of science, Ain Shams University, Abbassia, Cairo, 11566,Egypt
Keywords: Anti-cancer, topoisomerase II, DNA intercalators, quinoxaline, docking.
Abstract: Backgroun/Methods: In attempt to develop new potent anti-tumor agents, a series of quinoxaline derivatives was designed and synthesized. The novel compounds were tested in vitro for their anti-proliferative activities against HePG-2, MCF-7 and HCT-116 cell lines. Additionally, DNA binding affinities as well as DNA-top II inhibitory activities of the synthesized compounds were investigated as potential mechanism for anticancer activity. Compounds 13, 15, 16 and 19 exhibited good cytotoxicity activities against the three cell lines (IC50 ranging from 7.6 to 32.4 µM) comparable to that of doxorubicin (IC50 = 9.8 µM).
Results: Interestingly, the results of DNA binding and DNA-top II inhibition assays were in agreement with those of the cytotoxicity tests, where the most potent anticancer compounds showed good DNA binding affinities (IC50 ranging from 25.1 to 32.4 µM) and DNA-top II inhibitory activities (IC50 ranging from 6.4 to 15.3 µM) comparable to those of doxorubicin (IC50 = 28.1 and 3.8 μM, respectively). Furthermore, molecular docking studies were carried out for the new compounds in order to investigate their binding pattern with the prospective target, DNA-top II complex (PDB-code: 3qx3).
Export Options
About this article
Cite this article as:
Eissa H. Ibrahim , El-Naggar M. Abeer *, El-Sattar E.A. Abd Nour and Youssef S. A. Ahmed , Design and Discovery of Novel Quinoxaline Derivatives as Dual DNA Intercalators and Topoisomerase II Inhibitors, Anti-Cancer Agents in Medicinal Chemistry 2018; 18 (2) . https://dx.doi.org/10.2174/1871520617666170710182405
DOI https://dx.doi.org/10.2174/1871520617666170710182405 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial [Hot Topic: An Up-Date of Olive Oil and Bioactive Constituents in Health: Molecular Mechanisms and Clinical Implications (Executive Guest Editor: Catalina Alarcon de la Lastra Romero)]
Current Pharmaceutical Design Q-TOF LC/MS-based Untargeted Metabolomics Approach to Evaluate the Effect of Folate-Conjugated Cyclodextrins on Triple-Negative Breast Cancer Cells
Current Pharmaceutical Analysis Investigation of the pH Dependent Cytotoxicity of Paclitaxel Conjugated Gold Nanoparticles
Pharmaceutical Nanotechnology The Epigenetic Modification of Epigallocatechin Gallate (EGCG) on Cancer
Current Drug Targets Nanocarriers to Solid Tumors: Considerations on Tumor Penetration and Exposure of Tumor Cells to Therapeutic Agents
Current Pharmaceutical Biotechnology Modulating Fatty Acid Metabolism and the AMP-Activated Protein Kinase Pathway as a Target for Obesity Therapy
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Hollow Inorganic Nanoparticles as Efficient Carriers for siRNA Delivery: A Comprehensive Review
Current Pharmaceutical Design Epidermal Growth Factor Receptors: A Functional Perspective
Current Radiopharmaceuticals Long Term Recovery of Diaphragmatic Function in a Patient with Unilateral Diaphragmatic Pacemaker
Current Respiratory Medicine Reviews Delivery Systems for RNA Interference Therapy: Current Technologies and Limitations
Current Gene Therapy Molecular Response to Hypericin-Induced Photodamage
Current Medicinal Chemistry Photodynamic Therapy: The Light Treatment for Cutaneous Non- Melanoma Malignancies
Current Cancer Therapy Reviews Antagonists of Growth Hormone-Releasing Hormone in Oncology
Combinatorial Chemistry & High Throughput Screening Gold Nanoparticles as Carrier(s) for Drug Targeting and Imaging
Pharmaceutical Nanotechnology Molecules of Parasites as Immunomodulatory Drugs
Current Topics in Medicinal Chemistry Transcription Factors in Asthma: Are Transcription Factors a New Target for Asthma Therapy?
Current Drug Targets ATP-Binding Cassette Efflux Transporters in Human Placenta
Current Pharmaceutical Biotechnology A Bioinformatics Pipeline for Cancer Epigenetics
Current Bioinformatics Cellular and Molecular Targeted Drug Delivery: Nanochemistry in Medical Theranostics
Current Topics in Medicinal Chemistry Natural Medicine:The Genus Angelica
Current Medicinal Chemistry